<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649231</url>
  </required_header>
  <id_info>
    <org_study_id>13/0253.</org_study_id>
    <nct_id>NCT02649231</nct_id>
  </id_info>
  <brief_title>Ketamine for Reduction of Alcoholic Relapse</brief_title>
  <acronym>KARE</acronym>
  <official_title>Reducing Relapse in Severe Alcohol Use Disorder With the NMDA Receptor Antagonist Ketamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine
      (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3
      sessions of ketamine or placebo plus simple psychoeducation. Patients will be assessed at 3
      and 6 months on a range of psychological and biological variables. Primary endpoints will be
      % days abstinent at 3 and 6 months and relapse rates at 6 months. Secondary endpoints include
      depressive symptoms, craving, quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rates</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Primary Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine+Psychological Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine with psychological therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine+Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketamine with alcohol education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Psychological Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo with psychological therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Education</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo with simple alcohol education</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.8 mg/kg ketamine</description>
    <arm_group_label>Ketamine+Psychological Therapy</arm_group_label>
    <arm_group_label>Ketamine+Education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline</description>
    <arm_group_label>Placebo+Psychological Therapy</arm_group_label>
    <arm_group_label>Placebo+Education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychological Therapy</intervention_name>
    <description>Manualised relapse prevention based CBT</description>
    <arm_group_label>Ketamine+Psychological Therapy</arm_group_label>
    <arm_group_label>Placebo+Psychological Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Alcohol Education</intervention_name>
    <description>Simple education about alcohol effects</description>
    <arm_group_label>Ketamine+Education</arm_group_label>
    <arm_group_label>Placebo+Education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet either a) DSM-5 criteria for severe alcohol use disorder and b) DSM-IV criteria
             for alcohol dependence within the last 12 months;

          -  Currently abstinent from alcohol (breathalyser BAC level 0.00) and negative urine drug
             screening (participants testing positive for THC who do not have a history or current
             cannabis dependency may be included);

          -  Minimum of mild depression(&gt;14 on Beck Depression Inventory-II);

          -  Capacity to give informed consent as defined by GCP guidelines;

          -  Willing and able to wear SCRAM-X bracelet for 6 months;

          -  Females of childbearing potential and males must be willing to use an effective method
             of contraception (hormonal or barrier method of birth control; True abstinence) from
             the time consent is signed until 6 weeks after treatment discontinuation and inform
             the trial if pregnancy occurs. For the purpose of clarity, True abstinence is when
             this is in line with the preferred and usual lifestyle of the subject. Periodic
             abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods),
             declaration of abstinence, withdrawal, spermicides only or lactational amenorrhoea
             method for the duration of a trial, are not acceptable methods of contraception;

          -  Females of childbearing potential must have a negative pregnancy test within 7 days
             prior to being registered for trial treatment and on day of first treatment.

        Exclusion Criteria:

          -  Currently taking any other relapse prevention medication or anti-depressants;

          -  Uncontrolled hypertension, systolic 140mm Hg or greater and diastolic 90mm Hg or
             greater;

          -  &lt;16 or &gt; 35 BMI

          -  History of psychosis, or in a first-degree relative as identified by DSM-5 or DSM-IV
             SCID; co-morbid current psychiatric diagnosis excluding depression, identified via
             self-reported or identified by a medical professional;

          -  Previous or current diagnosis of substance dependence / severe substance misuse
             disorder;

          -  History of neuropsychological difficulties

          -  One or more previous confirmed seizures;

          -  Currently taking daily prescribed medication contraindicated in the SPC with ketamine:

               1. Barbiturates and/or narcotics

               2. Atracurium and tubocurarine

               3. Central nervous system (CNS) depressants (e.g. phenothiazines, sedating H1 -
                  blockers or skeletal muscle relaxants)

               4. Anxiolytics, sedatives and hypnotics

               5. Thiopental, thyroid hormones

               6. Antihypertensive agents

               7. Theophylline and methylxanthines.

               8. Halogenated anaesthetics

               9. OR psychotropic drug use at screening assessments or during treatment weeks

          -  Liver function tests &gt; 3 times normal levels

          -  Where there are &quot;special warnings or precautions for use&quot; according to the SPC and
             where risk vs benefit ratio is not in favour of giving ketamine, with assessment made
             by physical examination by medically qualified trial personnel, self-report or
             inspection of the medical notes:

               1. Acute intermittent porphyria

               2. Dehydration or hypovolemia

               3. Hyperthyroidism, or patients receiving thyroid replacement

               4. Pulmonary or upper respiratory tract infection

               5. Severe Coronary artery disease, Cerebrovascular accident or cerebral trauma

               6. Diabetes

               7. Known glaucoma or globe injuries

               8. Cirrhosis

               9. Epilepsy

              10. Neurological condition/brain damage

              11. Intracranial mass lesions, presence of head injury or hydrocephalus

          -  Suicidal ideation.

          -  Not willing to use effective contraception or (females) take pregnancy test;

          -  Allergic reaction to ketamine;

          -  &gt;10 previous detoxifications from alcohol;

          -  Pregnant or breastfeeding;

          -  Allergies to excipients of IMP or placebo;

          -  Use of another experimental investigational medicinal product that is likely to
             interfere with the study medication within 3 months of study enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celia Morgan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy McAndrew, PhD</last_name>
    <email>a.mcandrew@exeter.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>NIHR Exeter Clinical Research Facility</name>
      <address>
        <city>Exeter</city>
        <zip>EX4 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy McAndrew, PhD</last_name>
      <phone>01392 724070</phone>
      <email>a.mcandrew@exeter.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIHR/Wellcome UCLH Research Facility</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Marsh, PhD</last_name>
      <phone>02076798275</phone>
      <email>b.marsh@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

